After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...